Novartis AG v. Union of India and Others

1. Case Citation and Basic Information 

Case Name: Novartis AG v. Union of India and Others 

Citation: (2013) 6 SCC 1 

Court: Supreme Court of India 

Bench: Justice Aftab Alam and Justice Ranjana P. Desai 

Date of Decision: 1 April 2013  

2. Introduction 

The decision in Novartis AG v. The case of Union of India is one of the greatest rulings in the  Indian patent law, especially patent related to pharmaceuticals and national health policy. The case  involved patentability of the beta crystalline form of Imatinib Mesylate, which is a medication in  treatment of chronic myeloid leukemia and is sold in the market under the name Glivec. The main  point of contention was the interpretation of the meaning of the section 3 (d) of the patent Act,  1970, which only permits patenting new forms of the known substances unless they exhibit new  therapeutic effects. This decision by the Supreme Court has clarified the concept and the definition  of therapeutic efficacy and strengthened the policy of India in preventing evergreening of  pharmaceutical patents. The decision has impacted extensively on the pharmaceutical invention,  availability of medicines, and the nature and weighting of intellectual property protection versus  health-related interests of the people. 

3. Facts of the Case 

The controversy started with a patent application that Novartis AG according to which it is a  multinational pharmaceutical company applied to the beta crystal of Imatinib Mesylate (b-IM). Imatinib is a name given to the compound, which was first discovered by Dr. Jurg Zimmermann  in the United States in Patent No. 5,521,184 in 1996. The discovery was the derivatives of N phenyl-2-pyrimidine-amine and it was applicable in the treatment of some cancers. The compound  was then later turned into a salt form Imatinib Mesylate by Novartis, which would then proceed to  produce the beta crystalline form of the compound that was said to have superior properties  including stability, bioavailability, and flow properties. The medication was sold to the whole  world under the brand name, Glivec, as a therapeutic agent of chronic myeloid leukemia and other  cancer types. In 1998, Novartis registered a patent in India of Imatinib Mesylate in its beta  crystalline form. Indian patent regime at the time did not allow pharmaceutical product patents. The application on the other hand was kept in the system of the mailbox awaiting amendments and  revision to the Patents Act as per the obligation of India as per the TRIPS Agreement. This was the  same time that Novartis acquired the Exclusive Marketing Rights (EMR) in India, in 2003, to the  drug. After the modification in the Patents Act 2005 that brought in the product patent in the  pharmaceutical industry, the Indian Patent Office looked into the application. In 2006, the Assistant 

Controller of Patents turned down the application because the invention was unpatentable due to  it not being novel and was expected by earlier inventions, specifically the Zimmermann patent. Also, the Controller believed that the invention did not meet the conditions of Section 3(d) of the  Patents Act because the applicant did not prove increased therapeutic efficacy. Before the  Intellectual Property Appellate Board (IPAB), Novartis challenged the ruling. The IPAB believed  that the invention had passed the test of invention in accordance with Sections 2(1)(j) and 2(1) (ja),  but it had not passed the test of enhanced efficacy which was in accordance with Section 3(d). As  a result of this, the claim of patent was repudiated. Novartis was not pleased with the decision, and  appealed to the Supreme Court of India in regards to the IPAB order. The issue before the Supreme  Court was whether the beta crystalline version of Imatinib Mesylate met the needs of patentability  under the Patents Act, 1970, and especially whether it met the test of an improved therapeutic  effect under Section 3(d). 

4. Legal Issues 

• Whether the beta crystalline form of Imatinib Mesylate constituted a  “new invention” within the meaning of Sections 2(1)(j) and 2(1)(ja) of the  Patents Act, 1970.  
• Whether the claimed invention represented a “new form of a known  substance” under Section 3(d) of the Patents Act.  
• Whether the applicant had demonstrated “enhanced therapeutic  efficacy” of the beta crystalline form of Imatinib Mesylate as required  under Section 3(d).  
• Whether Section 3(d) operates as a substantive restriction on  patentability in pharmaceutical inventions aimed at preventing  evergreening.  

5. Arguments Presented 

Appellant’s Arguments (Novartis AG) 

Novartis argued that Imatinib Mesylate as well as the beta crystalline was a novel invention  through a two-stage inventive process. The appellant asserted that the initial compound Imatinib  was subjected to conversion to the mesylate salt form and further to the beta crystalline form which  had better properties than the free base form of the compound. The appellant contended that the  beta crystalline was much more physiochemically favorable such as thermodynamic stability, a  lower hygroscopicity, and bioavailability. These attributes as observed by Novartis helped to  improve the performance of the drug and made it more appropriate in therapeutic use. Novartis  also argued that the subject product should not be covered by the Section 3(d) as the provision is  just an explanatory or cautionary provision that does not form a separate basis of refusing to grant  patent applications. It stated that as soon as the invention had met the criteria of novelty and inventive step as stated in Sections 2(1)(j), and 2(1)(ja), then the patent ought to be awarded. Another argument that was put forward by the appellant was that section 3(d) of the act concerns  known substance, meaning those substances the efficacy of which has already been established. As the efficacy of Imatinib was not known before in India, the appellant argued that that the  provision did not apply to the beta crystal form of Imatinib Mesylate. 

Respondent’s Arguments (Union of India and Others) 

The respondents argued that Imatinib Mesylate was already disclosed in the Zimmermann patent  and therefore constituted a known substance. The beta crystalline form, being merely a  polymorphic form of the same substance, did not qualify as a new invention for the purposes of  patent protection. The respondents further contended that Section 3(d) was introduced specifically  to prevent the practice of “evergreening,” whereby pharmaceutical companies seek patent  protection for minor modifications of existing drugs to extend their monopoly period. According  to them, the provision requires proof of enhanced therapeutic efficacy in order to grant patents for  new forms of known substances. It was also argued that improvements such as increased stability  or bioavailability do not automatically establish enhanced therapeutic efficacy. The respondents  maintained that Novartis had failed to provide empirical or clinical evidence demonstrating that  the beta crystalline form produced superior therapeutic outcomes compared to the known  substance. 

6. Court’s Reasoning and Analysis 

The Supreme Court has made an elaborate technical review of the history of legislation and intent  of the Section 3(d) of Patents Act. The Court noted that the clause was added in the 2005  amendments to ensure it complied with the TRIPS obligations and at the same time assures the  citizens access to affordable medicines. The Court stated that the Patents Act makes a distinction  between the notions of the invention and the patentability. Though a product can be an invention  under Section 2(1)(j), it could be non-eligible to patent protection by Section 3. Consequently, the  subject product should pass the test of invention and the test of patentability. Concerning the  definition of efficacy, the Court ruled that efficacy, applied to the case of pharmaceutical products,  had to be considered as meaning therapeutic efficacy. This is an aspect of the capability of the drug  to do the therapeutic effect one wants to achieve when treating a disease. Increase in characteristics  like solubility or stability can be crime-solving but not necessarily go towards building higher  therapeutic efficacy. The Court also remarked that the Imatinib Mesylate beta crystal form  potentially exhibits the better physicochemical properties; nevertheless, Novartis did not provide  through any empirical evidence that the improvement would result in the greater therapeutic effect  when compared with the known substance. The Court also dismissed an argument to the effect that  Section 3(d) is a clarificatory section. Rather, it believed that the provision would put in place a  second level of patentability requirements in the case of chemical and pharmaceutical substances  to avoid accusations of the duplication of patenting known drugs. Based on this, the Court held  that the beta crystalline form of Imatinib Mesylate was a novel form of a known compound and that the applicant had not shown any superior therapeutic properties as demanded by the Section  3(d). 

Judgment and Ratio Decidendi 

The Supreme Court, rejected the appeals made by the Novartis AG and affirmed the Intellectual  Property Appellate Board. The Court decided that Imatinib crystal Mesylate, which is a beta crystal  form did not qualify to be patented under the Patents Act, 1970. 

Decision 

The Supreme Court dismissed the appeals filed by Novartis AG and upheld the decision of the  Intellectual Property Appellate Board. The Court held that the beta crystalline form of Imatinib  Mesylate did not qualify for patent protection under the Patents Act, 1970.  

Ratio Decidendi 

The ratio decidendi decision is that according to Section 3(d) of the Patents Act a new form of a  known pharmaceutical substance cannot be patented unless the applicant shows that it has a better  therapeutic effect than known substance. Physicochemical functions like improved bioavailability  or stability must be improved unless they have been proven to lead to a better therapeutic effect. 

7. Critical Analysis 

Significance of the Decision 

The judgment represents a landmark interpretation of Section 3(d) of the Patents Act and  establishes a rigorous standard for patentability in pharmaceutical inventions. It clarified the  distinction between invention and patentability and reaffirmed the legislative intent to prevent  evergreening practices in the pharmaceutical sector. 

Implications and Impact 

The decision has had significant implications for access to medicines in India and other developing  countries. By refusing patent protection for minor modifications of existing drugs, the ruling  allows generic manufacturers to produce affordable versions of life-saving medicines. The  judgment has also influenced global debates regarding the balance between intellectual property  protection and public health. 

8. Critical Evaluation 

While the decision has been widely praised for promoting access to affordable medicines, it has  also attracted criticism from sections of the pharmaceutical industry. Critics argue that the stringent  interpretation of Section 3(d) may discourage incremental innovation in drug development.  Nevertheless, the Court’s reasoning reflects a deliberate policy choice to priorities public health  considerations while still allowing patents for genuine pharmaceutical innovations.

9. Conclusion 

Novartis AG the ruling of the Supreme Court. Union of India is a landmark in the history of the  Indian patenting law. The Court used the literal interpretation of Section 3(d) to broaden India  dedication in avoiding evergreening and limiting the terms of patent protection on only truly  innovative inventions. The decision made it clear that the requisite conditions to patent new forms  of well recognized pharmaceutical substances are achievement of greater therapeutic efficacies. 

Finally, the judgment is a wise compromise between upholding intellectual property rights and  protecting access to cheap medicines to the populace. It still remains influential on the  pharmaceutical patent jurisprudence in India and the world at large.